RESEARCH ARTICLE

Linear and Conformational B Cell Epitope Prediction of the HER 2 ECD-Subdomain III by *in silico* Methods

Manijeh Mahdavi¹, Hassan Mohabatkar²*, Mehrnaz Keyhanfar², Abbas Jafarian Dehkordi¹, Mohammad Rabbani¹

Abstract

Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, c-erbB2 or HER2/neu, is a 185 kDa protein (p185) involved in signal transduction as well as regulating cell growth. Since the discovery of the role of HER2 in tumorigenesis, it has received great attention in cancer research and vaccine design during the past two decades (Tai et al., 2010). HER2 is a transmembrane glycoprotein contains three distinct regions: N-terminal extracellular domain (ECD), a single transmembrane α-helix (TM), and an intracellular tyrosine kinase domain. The largest part of HER2, the N-terminal ECD composed of approximately 600 residues (90–110 kDa) which could be divided into four subdomains (I–IV). Subdomains I (residues 23-217) and III (343-510) created a binding site for the receptor’s potential ligands (Lax, 1988). While the cysteine-rich subdomains II (218-342) and IV (511-582) are involved in the homodimerization and heterodimerization (Fiore, 1987; Pietras, 1995). HER2 is highly expressed in a significant proportion of breast, ovarian, gastric, colon, prostate and lung cancers. HER2 overexpression in these cancers often correlates with tumor metastasis, making it an attractive target for cancer immunotherapy (Siyi et al., 2008). Recently, several monoclonal antibodies (MAbs) against HER2 ECD have been developed for clinical applications of cancer diagnosis and therapy (Yum and Robyn, 2002). Although, the majority of these antibodies can inhibit tumor cell growth with various efficiencies *in vitro* and *in vivo*, some of them have not any inhibiting effects or even stimulate tumor cell growth. In addition, the diverse functions of anti HER2 antibodies appear to be correlated to their paratopes specificity (Boyer et al., 1999). It was suggested that anti HER2 antibodies with different epitopes can have distinct effects on HER2 physiological functions and changes its signaling properties (Wang et al., 2004). Pertuzumab, also called Omnitarg is a humanized MAb and HER dimerization inhibitor, binds to the dimerization arm (Subdomain II) of HER2 and prevents its dimerization with other HER family members (Franklin et al., 2004). Trastuzumab also denoted Herceptin, is another recombinant humanized MAb that targets Subdomain IV, close to the transmembrane domain, and in several studies its therapeutic efficacy has been confirmed in HER2 overexpressing metastatic and early stage breast cancer (Cho et

*1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences, 2Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan, Iran  *For correspondence: h.mohabatkar@ast.ui.ac.ir

Asian Pacific Journal of Cancer Prev, 13, 3053-3059

Introduction

Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, c-erbB2 or HER2/neu, is a 185 kDa protein (p185) involved in signal transduction as well as regulating cell growth. Since the discovery of the role of HER2 in tumorigenesis, it has received great attention in cancer research and vaccine design during the past two decades (Tai et al., 2010). HER2 is a transmembrane glycoprotein contains three distinct regions: N-terminal extracellular domain (ECD), a single transmembrane α-helix (TM), and an intracellular tyrosine kinase domain. The largest part of HER2, the N-terminal ECD composed of approximately 600 residues (90–110 kDa) which could be divided into four subdomains (I–IV). Subdomains I (residues 23-217) and III (343-510) created a binding site for the receptor’s potential ligands (Lax, 1988). While the cysteine-rich subdomains II (218-342) and IV (511-582) are involved in the homodimerization and heterodimerization (Fiore, 1987; Pietras, 1995). HER2 is highly expressed in a significant proportion of breast, ovarian, gastric, colon, prostate and lung cancers. HER2 overexpression in these cancers often correlates with tumor metastasis, making it an attractive target for cancer immunotherapy (Siyi et al., 2008). Recently, several monoclonal antibodies (MAbs) against HER2 ECD have been developed for clinical applications of cancer diagnosis and therapy (Yum and Robyn, 2002). Although, the majority of these antibodies can inhibit tumor cell growth with various efficiencies *in vitro* and *in vivo*, some of them have not any inhibiting effects or even stimulate tumor cell growth. In addition, the diverse functions of anti HER2 antibodies appear to be correlated to their paratopes specificity (Boyer et al., 1999). It was suggested that anti HER2 antibodies with different epitopes can have distinct effects on HER2 physiological functions and changes its signaling properties (Wang et al., 2004). Pertuzumab, also called Omnitarg is a humanized MAb and HER dimerization inhibitor, binds to the dimerization arm (Subdomain II) of HER2 and prevents its dimerization with other HER family members (Franklin et al., 2004). Trastuzumab also denoted Herceptin, is another recombinant humanized MAb that targets Subdomain IV, close to the transmembrane domain, and in several studies its therapeutic efficacy has been confirmed in HER2 overexpressing metastatic and early stage breast cancer (Cho et
Mahdavi Manijeh et al

of HER2 due to the role of this subdomain in formation of ligand binding site for the receptor; we are trying to focus of pathogenesis and immunological research as well as to develop novel humanized recombinant MAbs for HER2. Afterwards, anti-HER2 MAb muA21 and CH401 were developed (Wang et al., 2000; Ishida et al., 1994). MAb muA21 was found specifically inhibited the growth of the human breast cancer SK-BR-3 cells and MAb CH401 had cytotoxicity against HER2 expressing tumor cells. These MAbs were targeted the subdomain I of HER2 ECD.

HER2 is also considered as a target for vaccine development for primary prevention of cancers (Wiwanitkit, 2007). Although passive immunotherapy with trastuzumab is approved for treatment of breast cancer, a number of concerns exist with passive immunotherapy. For instance, the treatment is expensive, has a limited duration of action, and necessitates repeated administrations of the MAb. Active immunotherapy with synthetic peptide B-cell epitopes increases the possibility of generating an adaptive immune response, eliciting protein reactive high affinity MAbs (Garrett et al., 2007). Therefore, there is a need to further explore new epitopes of HER2 ECD and utilize them as peptide vaccine. Identification and selection of suitable epitopes is a time-consuming, expensive and difficult work requiring accurate experimental screening. Hence, cheaper strategies such as computational predictions could be used for faster and cheaper screening. Today, there are many bioinformatics tools available that can be used as primary screening step to identify targets of interest more efficiently (Chen et al., 2011). But there are limitations; it is not possible to develop an exact algorithm, consider to the defective knowledge about the immune response and these methods are working approximately well. Moreover, the prediction results produced by different tools may have distinct differences and multiple tools should be used to gain a consensus result. Therefore, in the current research new linear and conformational B-cell epitopes were predicted by combination of bioinformatics analyses.

B-cell epitopes are defined as regions on the surface of the native antigen that are recognized and bind to B-cell receptors or specific antibodies. B-cell epitopes can be categorized into two types: linear (continuous) epitopes and conformational (discontinuous) epitopes (Zhang et al., 2011). Linear epitopes comprise residues that are continuous in the sequence, while conformational epitopes consist of residues that are distantly separated in the sequence but have spatial proximity. These epitopes are the focus of pathogenesis and immunological research as well as the targets of development of vaccine, cancer therapy and diagnostic reagent (Jiang et al., 2010). Our studies showed that there is no MAb that targets subdomain III of HER2 due to the role of this subdomain in formation of ligand binding site for the receptor; we are trying to design B cell epitopes in the subdomain III. Therefore, the identification of B-cell epitopes for subdomain III of HER2 ECD can provide important information for the development of new MAb and cancer vaccines that target different epitopes or structural domains of HER2 ECD. In the present study, the linear and conformational B-cell epitopes of HER2 ECD were screened and identified using bioinformatics comprehensive analyses. An integrated strategy was employed for B cell epitope prediction by combining results from sequence and structure based methods and protein-protein interaction tools. Furthermore, we used SUPERFICIAL software that based on protein structures and generates library proposals including linear and nonlinear peptides.

Materials and Methods

Prediction of B cell epitopes by integrated strategy

For determination of linear epitopes, the sequence of ECD HER2 receptor was submitted to ABCpred, BCPREDS, Bcepred, Bepipred and Ellipro web servers (Saha and Raghava, 2004; 2006; Larsen et al., 2006; Ponomarenko et al., 2008; Manzalawy et al., 2008a,b). For prediction of discontinuous or conformational epitopes, the PDB structures: 1N8Z, 1S78, 2A91 and sequence based PDB structure obtained by m4t server, a fully automated comparative protein structure modeling server (http://www.fiserlab.org/servers/m4t) was submitted to Discotope 1.2 server (Haste Andersen et al., 2006). Also CBtope was used to predict conformational B cell epitopes using antigen primary sequence (Ansari et al., 2010). Protein-protein interaction sites on the PDB structures were predicted using cons PPISP online tool (Bradford and Westhead, 2005). Solvent accessibility of all the residues was calculated by ASAView (http://www.netasa.org/asaview). Absolute surface area (ASA) of each residue was calculated by DSSP program. These values were transformed to relative values of ASA. Default settings were applied to all the tools used. The regions recognized frequently by four or more than four tools were selected. The protein structures were analyzed and viewed with PyMOL V 1.

Secondary Structure Prediction

The secondary structure was predicted using PHD (http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_phd.html) and PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/) fold servers. The secondary structure prediction results were used for conformational B-cell epitope identification by integrated strategy.

Theoretical physico-chemical properties of the peptides

The theoretical physicochemical properties of the synthetic peptides (such as the ionization status, calculated as the isoelectric point, and the hydrophobicity, measured as the grand average of hydrophaticity (GRAVY) index) were analyzed using the Prot Param algorithm (http://www.expasy.ch/tools/protparam.html). The GRAVY index indicated the hydrophobicity of the peptide and was calculated as the sum of the hydrophathy values (Kyte and Doolittle parameters) of the composing amino acids.
acids, divided by the number of residues in the sequence. Peptides with positive GRAVY index are hydrophilic whereas peptides with negative GRAVY index are hydrophobic (Lebreton et al., 2011).

**Prediction of B cell epitopes by SUPERFICIAL software**

We used SUPERFICIAL (http://bioinformatics.charite.de/superficial) a structure-based program for designing of peptide libraries that mimic the whole surface or a particular region of a protein. It automatically defines the protein surface, using preset default values useful to a range of proteins. SUPERFICIAL uses protein structures (PDB codes) as input and generates library proposals consisting of linear and nonlinear peptides. Neighboring sequence segments are linked by short spacers to conserve local conformation. All generated peptides are listed within a table. Such a structure-based peptide library provides the source for chemically-prepared peptides to identify and characterize binding sites, respectively (Goede et al., 2005).

**Sequence Alignment**

Amino acid sequence of ECD of human and mouse ErbB2 receptor and peptides (P1, P2) was aligned using Cobalt Constraint-based Multiple Protein Alignment Tool (http://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?link_loc=BlastHomeAd) and The Universal Protein Resource (UniProt)/Align (http://www.uniprot.org/) with default parameters. The output was manually checked to optimize the alignment.

**Results**

**Prediction of B cell epitopes by integrated strategy**

The predicted linear B-cell epitopes of subdomain III of HER2 ECD are shown in Table 1. For each peptide, sequence, position, molecular weight, isoelectric pH and gravy score was indicated. As shown in Table 1, P5 and P15 are recognized frequently by four and five tools used in this work. These peptides are related to regions 379-394 and 491-506, respectively. P8 and P12 were only identified by ABCpred.

Furthermore, in CBtope software four conformational B-cell epitope regions were identified which two of them were in the region of linear B-cell epitopes (376-394 and 492-508). Also conformational B-cell epitope (376-394) was identified by discotope server (Table 2). Further analyses for protein-protein interaction sites and solvent accessibility of all the residues on the PDB structures using cons PPISP and ASAView online tools defined that B cell epitopes of 378-393 (PESFDGDPASNTAPLO), P1, and 500-510 (PEDECVGEGLA), P2, have higher solvent accessibility and their residues are exposed on the surface (Figure 1). These are important factors for immunogenicity of an antigen or synthetic peptide. Around 43% of the 170 residues (in subdomain III) were non polar, 22% were charged residues and 34% were recorded as polar residues for subdomain III of HER2 ECD. The relative surface accessibility values calculated by ASAView showed 34.91% residues with greater than 30% whereas 27.81% residues were with greater than 50% solvent accessibility. Cons PPISP online tool was determined buried residues, 40.24% of residues in subdomain III of HER2 ECD were

**Table 1. The 16mer Peptides Linear B-cell Epitopes Predicted from Subdomain III of HER2 ECD by Different Linear B-Cell Epitope Prediction**

| Gravy score | Pl   | Mw (Da) | Softwares | Position | Sequence | Peptidea |
|------------|------|---------|-----------|----------|----------|----------|
| -1.337     | 4.87 | 1783.9  | 1,2,3,5   | 321-336  | EVTADGGTQRCEKCSK | *P1 |
| -0.194     | 6.76 | 1818    | 1,3       | 343-358  | YGLMEHRLREVARTVS | *P2 |
| 0.231      | 8.24 | 1679.9  | 1,4,5     | 355-370  | AVTSANIQEAGCKKI | *P3 |
| 0.4        | 6.06 | 1802.1  | 1,2       | 367-382  | CKKIFGLAFLPESFD | *P4 |
| -0.925     | 3.49 | 1645.7  | 1,2,3     | 379-394  | ESFDGDPASNTAPLO | *P5 |
| -0.35      | 4    | 1739.9  | 1,2       | 385-400  | PASNTAPLOPEQLQVF | *P6 |
| -0.188     | 3.56 | 1830    | 1,2       | 392-407  | AWPDLSLDSVFQNLQ | *P7 |
| 0.006      | 3.57 | 1857    | 1         | 403-418  | LEEIGYLYISAWFPS | *P8 |
| 0.163      | 3.56 | 1838    | 1,2       | 411-426  | YISAWPDLSVPFQVF | *P9 |
| 0.269      | 10.84| 1810.1  | 1         | 428-443  | LQVIRGRILHNGAYS | *P10 |
| 0.406      | 9.6  | 1757    | 1,2       | 448-463  | LGISWGLRSRELGS | *P11 |
| 0.713      | 7.01 | 1733    | 1         | 461-476  | LGSGALIHHNTLCF | *P12 |
| 0.35       | 7.09 | 1954.2  | 1,2,3     | 467-482  | LIHHNHTLCVHTVPW | *P13 |
| -0.806     | 6.89 | 1945.1  | 1,2       | 477-492  | VHTVPWDQFLRNPQHA | *P14 |
| -0.625     | 4.65 | 1752.9  | 1,2,3     | 491-506  | QALHITANRPEDCVG | *P15 |
| -0.312     | 4.79 | 1975.2  | 1,2,3     | 519-535  | VECCRVLQLPREYVNA | *P16 |

*Hydrophobic Peptide are starred (i.e. *P1), *Tools that recognized the corresponding B cell epitopes or part of the epitope are numbered as follows: ABCpred (1), BepiPred (2), Bcepred (3), BCpred (4), Ellipro (5).
Table 2. Predicted Conformational B Cell Epitopes

| Sequence* | Residue no | Position | Softwares |
|-----------|------------|----------|-----------|
| FLPEFDGDPSNATAPLQ | 17 | 376-394 | CBope, Discotope |
| EQNLQVRIRGRLIN | 9 | 425-438 | CBope |
| ALLHTANRPEDCVGEGL | 14 | 492-508 | CBope |
| GHCWPGPQTVCNCSQFLRGEQL | 17 | 518-539 | CBope |

*Peptide residues are indicated as Bold and underlined, Hydrophobic Peptides are starred (i.e *P1)

Figure 3. Multiple alignments between peptides (P1c, P2c) and ErbB2 ECD of human and mouse using Cobalt Constraint-based Multiple Protein Alignment Tool.

In Table 3 and 4, linear and nonlinear peptides were shown, respectively. Linear peptides were predicted by SUPERFICIAL software was similar to Linear B cell epitopes was obtained by integrated strategy (Table 1). In Table 4, conformational B-cell epitopes P4-P9 were in the region of P1c: 378-394 of HER2 ECD subdomain III and also P13-15 was nearly similar to P2c. SUPERFICIAL predicted new conformational B cell epitope or nonlinear peptides such as P1-3 and P10-12. To preserve their conformation, the gaps between the peptide-fragments are filled with linkers, short amino acid sequences derived from the LIP (Loops in Proteins) database (Michalsky et al., 2003). Certainly sometimes amino acids were represented by the character “X” that could be replaced in praxis by poly-Alanine and/or Glycine instead of using the Linker. Figure 2 is showing the 3D view of the predicted conformational B-cell epitope PEESFDGD-X-TAPLQ (378-385, 389-393) in SUPERFICIAL and Pymol softwares.

Sequence alignment

The sequence alignment between ECD of human and mouse ErbB2 receptor isofrom using UniProt was shown 85.42% identity, 539 identical positions and 63 similar positions. Additionally the sequence homology of predicted HER2 peptides were tested between the human and mouse ErbB2 sequences (Figure 3). It was shown these peptides had homology of 100% with HER2 ECD. This alignment was also indicated 64 and 50% homology of peptides P1c and P2c with mouse ErbB2 ECD, respectively. These results were described the rate of foreignness of HER2 ECD for immunization of mouse. It should be noted the foreignness is a very important factor.

Table 3. The Linear B-Cell Epitopes Predicted from Subdomain III of Her 2 ECD by SUPERFICIAL Software.

| PDB code | Position | Residue no | Sequence | Peptide |
|----------|----------|------------|----------|---------|
| 1NZX | 1IS8, 2A91, M4T | 342-355 | CYGLMEHREVRA | P1 |
| 1IS8, 1NZX, 2A91, M4T | 362-369 | 8 QEFAGCKK | P2 |
| 1IS8, 2A91, M4T | 382-390 | 9 DGDPSANTA | P3 |
| 1IS8, M4T | 394-401 | 8 PEQLQVFE | P4 |
| 1IS8 | 434-439 | 6 RILHNG | P5 |
| 1IS8, 1NZX, 2A91, M4T | 483-489 | 7 DQIFRNP | P6 |
| 1IS8, 1NZX, 2A91, M4T | 495-518 | 24 HTANRPEDCVGEGL | P7 |
| 1IS8 | 529-533 | 5 VNCSQ | P8 |
Superficial software were predicted many of HER2 ECD had an alpha helical structure. In the second structure prediction results (PSIPRED), position 378-393 and conformational epitopes were approximately in the subdomain III of the receptor. Both of the linear epitopes was different from the previously reported epitopes for epitope P1.

Peptides were the linear B-cell epitopes P5: 379-394

Two different methods were used based on bioinformatics receptor from both primary sequence and tertiary structure. Improved methods for the prediction of conformational B cell epitopes. Examples are SUPERFICIAL software (Kulkarni-Kale et al., 2005; Haste et al., 2006).

Table 4. The Conformational or Non-Linear B-cell Epitope Regions Predicted from Subdomain III of Her 2 ECD by SUPERFICIAL Software

| PDB code          | Position       | Sequence       | Peptide | P |
|-------------------|----------------|----------------|---------|---|
| 1ST78B, 1NZ, m4t  | 362-369, 400-404 | QEFAGCKK-XXXX-FETLE | P1      |   |
| 2A91              | 362-368, 396-400  | QEFAGCKK-XXXXX-QLQVF | P2      |   |
| 2A91              | 362-369, 399-404  | QEFAGCKK-XXXX-VFETLE | P3      |   |
| 1ST78A, 1NZZ      | 378-384, 389-393  | PESFDGD-X-TAPLQ | P4      |   |
| 1ST8A             | 378-385, 389-393  | PESFDGD P X TAPLQ | P6      |   |
| 1ST8A             | 379-385, 388-394  | ESFDGD PNTAPLQP | P7      |   |
| 2A91              | 378-385, 389-393  | ESFDGD-X-TAPLQPEQL | P8      |   |
| 2A91              | 379-385, 388-394  | ESFDPD-X-NATLQQP | P9      |   |
| 1ST8B, 1NZ, m4t   | 395-404, 364-368  | EQLQVFETLE-XXXX-FAGCK | P10     |   |
| 1NZZ, m4t         | 396-400, 362-368  | QLQVF-XXXX-QEFGCK  | P11     |   |
| 1ST8B, 1NZ, m4t, 2A91 | 397-404, 364-369 | LQVFETLE-XXXXX-FAGCKK | P12     |   |
| 1NZZ, 2A91        | 509-518, 523-528  | LACHQLCARG-XXX-PGPTQCV | P13     |   |
| 1NZZ              | 510-515, 523-529  | ACHQLC-XXX-PGPTQCV | P14     |   |
| 1NZZ              | 510-518, 523-530  | ACHQLCARG-XXX-PGPTQCVN | P15     |   |

Discussion

Our study is the first to report the identification of novel conformational B-cell epitopes of HER2 ECD subdomain III. Despite of majority of epitopes being conformational, most of the computational methods and databases centered at the sequential epitopes (Vita et al., 2010). Linear epitope prediction methods can be categorized into physicochemical property, Hidden Markov Mode (HMM) and Artificial Neural Networks (ANN) based (Saha and Raghava, 2004; Larsen et al., 2006; Saha and Raghava, 2006). For this purpose, ABCpred, BCPREDs, Bepired, Bcprpred and Ellipro were used in this research. The tertiary structure of an antigen is known, there are improved methods for the prediction of conformational B cell epitopes. Examples are SUPERFICIAL software and Discotope web server (Goede et al., 2005; Haste Andersen et al., 2006; Moreau et al., 2008; Ponomarenko et al., 2008). These are based on features like flexibility, solvent accessibility and amino acid propensity scales (Kulkarni-Kale et al., 2005; Haste et al., 2006).

In the current study attempts have been made to predict linear and conformational B cell epitopes in HER2 receptor from both primary sequence and tertiary structure. Two different methods were used based on bioinformatics analyses. In the first method, integrated strategy, the best peptides were the linear B-cell epitope P5: 379-394 and P15:491-506 (Table 1) and conformational B-cell epitope P1c: 378-393 and P2c: 500-510 (Table 2) which was different from the previously reported epitopes for the subdomain III of the receptor. Both of the linear and conformational epitopes were approximately in the identical regions of HER2 ECD. Based on secondary structure prediction results (PSIPRED), position 378-393 of HER2 ECD had an alpha helical structure. In the second method, SUPERFICIAL software were predicted many new conformational peptide linked by the links (Table 4) and also this software is predicted conformational B-cell epitope P1c: 378-393 and P2c: 500-510 in the form of two segments or linear B-cell epitopes that are linked by the linker (Figure 2 and Table 3).

In the majority of the past studies on HER2 receptor, either Linear B cell epitopes or T-cell epitopes were used as synthetic peptide or antigen, while the vaccine peptides were designed to be chimeric with multi-epitopes of B-cells and helper T cells (Dakappagari et al., 2000; Montgomery et al., 2005). Synthetic peptides can be presented in different ways, such as conjugation to different carrier proteins, incorporation into liposomes, covalent conjugation to fatty acids and generation of multiple antigen peptides (MAP) (Haro and Gomara, 2004; Veje et al., 2011). Miyako et al. (2011) generated 22 kinds of synthetic MAPs containing 20 amino acid residues based on the region covering from N: 143 to N: 370 of HER2 ECD. They identified a new epitope of MAb CH401 against HER2 extracellular domain (N: 167-175), and evaluated the effect of active immunization of the 20mer peptide containing the epitope (CH401 peptide). The 20mer peptide (N: 163-182) including CH401 epitope (CH401 epitope peptide) was immunogenic, causing a high titer of peptide-specific IgG antibody in immunized BALB/c mice because it contained epitopes for both B-cells and helper T-cells. In contrast to the present study, these epitopes were located on subdomain I of HER2 ECD. In addition, Dakappagari et al. (2003) identified two linear HER2 ECD B cell epitopes (316–339 and 385–603) based on computer aid analyses. These epitopes incorporated to the measles virus fusion (MVF) 'promiscuous' T cell epitope via a four-residue linker sequence. They induced high titrated Abs inhibiting the growth of human breast cancer cells (Dakappagari et al., 2003). Moreover, Garrett et al. (2007) reported phase I clinical trial using the first generation peptide vaccines MVF 316-339 and MVF 628-647. They also used peptide constructs MVF 613-626, MVF 563-598 and MVF 597-626. All epitopes were immunogenic in FVB/n mice and 597-626 epitope significantly reduced cancer growth in transgenic BALB-neuT mice. Besides, Wiwanitiki (2007) predicted B cell epitopes of HER2 oncprotein by ABCpred prediction server. He determined the peptide 947SRMARDPQRFVVIQNE963 with the
best binding affinity. Thus, the finding of present work is different from those predicted epitopes or peptides of the previous studies (Dakappagari et al., 2003; Garrett et al., 2007; Wiwanitkit, 2007; Furthermore et al., 2009; Miyako et al., 2011) generated antibodies to linear epitopes of the HER2 that effect cell growth by a strategy based on polyclonal antibodies. The functional antibodies with growth inhibition properties located on domain II and III of the receptor, respectively. One of the epitopes mapped to domain II overlapped with the conformational epitope recognized by pertuzumab (266-296), while similar to our work, another epitopes on the surface of the domain III were close to each other in a linear stretch of 25 amino acids LPEFDGDPASNTAPLQPEQLQVF. Jasiinska et al. (2003) also identified seven B cell epitopes on sequence of HER2 ECD by computer analyses. The peptides (P1: 115–132AVLDNGDPLNNTTPTVGA; P2: 149–162LKGGVL IQRNPLC; P3: 274–295YN TDTTFESMP NP EGRYTFGAS; P4: 378–398PESFDGDPASN TAPLQPEQLQ; P5: 489–504PHQALLHTA NRPDE; P6: 544–560CRV LQGLP EYV NARHC; P7: 610–623YM PIWKFPDDEGAC were used for immunization, successfully induced humoral immune response with anti-tumor activity in an animal model. The linear peptide P5: 379-394 that we are predicted is similar to epitope P4: 378–398 which is used in Jasiinska et al. (2003) research. In another study, Dakappagari et al. (2005), designed a complex immunogen and conformational B-cell epitope peptide vaccine derived from the extracellular domain of HER2-(626–649) that represents a three-dimensional epitope. They successfully introduced two disulfide bonds into this sequence. Their study demonstrate the feasibility and importance of designing conformational epitopes that mimic the tertiary structure of the native protein for eliciting biologically relevant anti-tumor antibodies. Such approaches are a prerequisite to the design of effective peptide vaccines and immunogenic synthetic peptides. In the present work, new conformational B cell epitopes P1: 378-393 (PESFDGDPASNTAPLQ) and P2: 500-510 PEDECVGEGLA (Table 2) were predicted by bioinformatics analyses (integrated strategy and SUPERFICIAL software). These peptides are discontinuous parts of region 378-393 and 500-510 of HER2 ECD which were predicted with Linear B cell epitope tools.

Tolerance to self antigens such as HER2, may limit the functional immune response to whole protein based antigens due to activation of suppressor T cells that maintain tolerance to host Antigens (Disis and Cheever, 1997; Sakaguchi, 2000; Bonilla and Oettgen, 2010), while immunizing with peptides derived from self antigens may be an effective means of circumventing tolerance (Ercolini et al., 2003). However, it should be noted that peptides with a sequence identical to that of self antigen will not be able to break the threshold of self tolerance status and specific lymphocytes is expected to be deleted during the establishment of self identity. Mittelman et al. (2002) analyzed the similarity level of HER2 peptides to the host’s proteome and understand the relationship between molecular mimicry and peptide immunogenicity. They reported low level of sequence similarity to the host’s proteome plays an important role in shaping the pool of B cell epitopes and determining peptide immunogenicity. This finding has important implications in HER2 cancer therapy. For this purpose, in our study the foreignness or similarity level of peptides were evaluated by multiple sequence alignment. The results indicated lower similarity of peptides with mouse (Figure 3) compared to HER2 ECD. Furthermore, the peptides, P1c and P2c, are indicated high degree of foreignness (50 and 36%, respectively) for immunization of mice.

In conclusion, the findings of present work using bioinformatics analyses could be applied in MAb production, cancer therapy, developing vaccine design and diagnostic tools reducing the time and minimizing the total number of required tests to find possible proper epitopes. In the next step, in vitro synthesis of determined peptides and in vivo experimental studies are essential for prediction of the assured epitopes. In these experiments, identification of epitopes on HER2 that are either stimulatory or inhibitory is very important for development of strategies to better manipulate the Ab response for therapeutic benefit. Thus, selection of suitable epitopes from specific regions of HER2 capable of inducing cancer inhibitory MABs and careful elimination of epitopes that stimulate cancer cell growth, will be identified candidate peptides that could provide beneficial effects.

References

Ansari HR, Gajendra PS, Raghava GP (2010). Identification of conformational B-cell epitopes in an antigen from its primary sequence. *Immunol Res*, 6, 6.

Bonilla FA, Oettgen HC (2010). Adaptive immunity. *J Allergy Clin Immunol*, 125, 33-40.

Broyer CM, Pusztai L, Wiener JR, et al. (1999). Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erb-b2 (her-2/neu) gene product p185. *Int J Cancer*, 82, 525-31.

Bradford JR, Westhead DR (2005). Improved prediction of protein-protein binding sites using a support vector machines approach. *Bioinform*, 21, 1487-94.

Calabrish A, Fernandes GS, Katz A (2008). Trastuzumab: mechanisms of resistance and therapeutic opportunities. *Onkol (Williston Park)*, 22, 1250-8.

Chen P, Rayner S, Hu KH (2011). Advances of Bioinformatics tools applied in virus epitopes prediction. *Virologica sinica*, 26, 1-7.

Cho HS, Mason K, Ramyar KX, et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab. *Nature*, 421, 756-60.

Dakappagari NK, Lute KD, Rawale S, et al. (2005). Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. *J Biol Chem*, 280, 54-63.

Dakappagari NK, Pyles J, Parihar R, et al. (2003). Chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. *J Immunol*, 170, 4242-53.

Dakappagari N, Douglas D, Triozzi P, et al. (2000). Prevention
of mammary tumors with a chimeric Her-2 B-cell epitope peptide vaccine. Cancer Res, 60, 3782-9.

Disis ML, Cheever MA (1997). HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res, 71, 343-71.

Ercolini AM, Machiels JP, Chen YC, et al. (2003). Identification and character-ization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol, 170, 4273-80.

Fiore PD (1987). ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178-82.

Franklin MC, Carey KD, Vajdos FF, et al. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell, 5, 317-28.

Garrett JT, Kaumaya P, Pei D, et al. (2007). Peptide based B cell epitope vaccines targeting HER-2/Neu. Degree of doctor of philosophy thesis in the graduate school of the Ohio State University.

Goede A, Jaeger IS, Preissner R (2005). SUPERFICIAL--surface mapping of proteins via structure-based peptide library design. BMC Bioinform, 6, 223.

Haste Andersen P, Nielsen M, Lund O (2006). Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci, 15, 2558-67.

Ishida T, Tsujiaki M, Hinoda Y, et al. (1994). Establishment and characterization of mouse-human chimeric MAb to erbB-2 product. Jpn J Cancer Res, 85, 172-8.

Jasinska J, Wagner S, Radauer C, et al. (2003). Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of HER-2/Neu. Int J Cancer, 107, 976-83.

Jiang L, Zhou JM, Yin Y, et al. (2010). Selection and identification of B-cell epitope on NS1 protein of dengue virus type 2. Virus Res, 150, 49-55.

Kulkarni-Kale U, Bhosle S, Kolaskar AS (2005). CEP: a conformational epitope prediction server. Nucleic Acids Res, 33, 168-71.

Larsen JE, Lund O, Nielsen M (2006). Improved method for predicting linear B cell epitopes. Immunol Res, 2, 2.

Lax I (1988). Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Bio, 8, 1831-4.

Lebreton A, MoreauV, Lapalud P, et al. (2011). Discontinuous epitopes on the C2 domain of coagulation factor VIII mapped by computer-designed synthetic peptides. Brit J Hem, 155, 487-97.

Manzalawy Y, Dobbs D, Honavar V (2008). Predicting flexible length linear B-cell epitopes. 7th international conference on computational systems bioinformatics, CA, 121-31.

Manzalawy Y, Dobbs D, Honavar V (2008). Predicting linear B-cell epitopes using string kernels. J Mol Rec, 21, 243-55.

Michalsky E, Goede A, Preissner R (2003). Loops In Proteins (LIP)—a comprehensive loop database for homology modelling. Protein Eng, 16, 979-85.

Mittelman A, Luccchese A, Sinha A, Kanduc D (2002). Monoclonal and polyclonal humoral immune response to EC HER-2/Neu peptides with low similarity to the host,s proteome. Int J Cancer, 98, 741-7.

Miyako H, Kametani Y, Katano I, et al. (2011). Antitumor Effect of New HER2 peptide vaccination based on B cell epitope. Anticancer Res, 31, 3361-8.

Montgomery R, Makary E, Schiffman K, et al. (2005). Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal regulated kinase. Cancer Res, 65, 650-6.

Moreau V, Fleury C, Piquer D, et al. (2008). PEPOP: computational design of immunogenic peptides. BMC Bioinform, 9, 71.

Park JW (2008). Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer, 8, 392-401.

Pietras RJ (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 10, 2435-46.

Pomarenko J, Bui HH, Li W, et al. (2008). ElibPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform, 9, 514.

Richard A, Goldsby T, Kindt J, et al. (2000). Kubey Immunology. 5th ed. (W H Freeman and Co (Sd)).

Rockberg J, Schwenk JM, Uhle’n M (2009). Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies. Mol onco, 3, 238-47.

Saha S, Raghava GP (2004) BcePred:Prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. In: Nicosia G, Cutello V, Bentley PJ, Timis J, eds. ICARIS, Springer. Heidelberg. pp 197–204.

Saha S, Raghava GP (2006). Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins, 65, 40-8.

Sakaguchi S (2000). Regulatory T cells: key controllers of immunologic selftolerance. Cell, 101,455.

Siyi H, Zhiquiang Z, Liangwei L, et al. (2008). Epitope mapping and structural analyses of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins, 70, 938-49.

Tai W, Mahato R, Cheng K (2010). The role of HER2 in cancer therapy and targeted drug delivery-Review. J Control Rel, 146, 264-75.

Veje Axelsena T, Holma A, Christiansena G, et al. (2011). Identification of the shortest AB-peptide generating highly specific antibodies against the C-terminal end of amyloid-B42. Vaccine, 29, 3260-9.

Vita R, Zarebski L, Greenbaum JA, et al. (2010). The immune epitope database 2.0. Nucleic Acids Res, 38, 854-62.

Wang C, Li Y, Li P (2000). Generation and Characterization of monoclonal antibodies specific for the oncogene product P185 new/c-erbB-2 by surface epitope masking (SEM). J Chin Immune, 16, 539-41.

Wang JN, Feng JN, Yua M, et al. (2004). Structural analyses of the epitopes on erbB2 interacted with inhibitor or non-inhibitor monoclonal antibodies. Mol Immune, 40, 963-9.

Wiwanitkit V (2007). Predicted B-cell epitopes of HER-2 oncprotein by a bioinformatics method: a clue for breast cancer vaccine development. Asian Pac J Cancer Prev, 8, 137-8.

Yum LY, Robyn LW (2002). Anti-ErbB2 monoclonal antibodies and ErbB2-directed vaccines. Cancer Immune Immunother, 50, 569-87.

Zhang W, Xiaoyi Z, Zhao M, et al. (2011). Prediction of conformational B-cell epitopes from 3D structures by random forests with a distance-based feature. BMC Bioinform, 12, 341.